Each vial contains cefuroxime sodium equivalent to 250-750 mg cefuroximeMultisef IM
Each vial contains cefuroxime sodium equivalent to 250-750 mg cefuroxime. Each diluent ampoule contains 1- 3 mL 1% lidocain hydrochloride solution. The preparation is sterile apyrogen.
Multisef is indicated in the treatment of infections caused by susceptible strains of designated microorganisms in the diseases listed below:
Multisef is contraindicated in patients with known hypersensitivity to cefuroxime and cephalosporins.
Although there is cross-resistance between penicillin and cephalosporin group of antibiotics, cefuroxime can be administered when necessary to patients with penicillin allergy. In this case it should be given with caution. In severe cases of sensitivity, epinephrine and other emergency measures should be applied. Pseudomebranous colitis has been reported with the use of cephalosporins (and other wide spectrum antibiotics); if diarrhea occurs, the drug should be discontinued promptly. Safety of cefuroxime administration in pregnant women has not been established. It is also not recommended for nursing mothers. Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins. Cefuroxime should not be used in children below the age of 3 months.
Cefuroxime is generally well tolerated and local or systemic reactions listed below are the most common adverse effects which have been encountered rarely;
There is no report on the interaction of cefuroxime with any other drug. A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedict’s or Fehling’s solution or with Clinitest tablets), but not with enzyme-based tests for glycosuria. A false negative reaction may occur in the ferricyanide test for blood glucose.
Multisef injection can be administered intramuscularly or intravenously.
Multisef IM 750 mg vial for injection should be administered intramuscularly.
Preparing Solution for Intramuscular Use
Each 250 mg vial of MULTISEF should be constituted with 1 mL of sterile water for injection. Each 750 mg vial of MULTISEF should be constituted with 3 mL of sterile water for injection. Shake gently to disperse and withdraw completely the resulting suspension for injection.Multisef IM
Multisef 250 mg IM vial for injection 1mL is diluted with Multisef 750 mg IM vial for injection 3 mL diluent and shaken until an opaque suspension is obtained. All of the suspension is withdrawn into the injector and administered intramuscularly. Diluted suspensions are stable for 24 hours at room temperature and for 48 hours in the refrigerator.
Preparing Solution for Intravenous Use
Each 250 mg vial of MULTISEF should be constituted with 2 mL of sterile water for injection. Each 750 mg vial of MULTISEF should be constituted with 6 mL of sterile water for injection. Withdraw completely the resulting solution for injection. It can be administrated either directly in intravenous way or into the parenteral set.
In managing overdosage, the patient's airway should be protected and ventilation and perfusion supported. Patient's vital signs, blood gases and serum electrolytes should be meticulously monitored and maintained. If the patient develops convulsions, the drug should be promptly discontinued; anticonvulsant therapy may be administered if clinically indicated.
Should be kept out of reach of children, at room temperature (<25ºC) and in its package.
MULTISEF IM 250 mg vail containing powder for injection, 1 vial + 1 diluent ampoule (1 mL)
MULTISEF IM 750 mg vail containing powder for injection, 1 vial + 1 diluent ampoule (3 mL)
MULTISEF for injection 250 mg, 1 vial + 1 diluent ampoule (2 mL)
MULTISEF for injection 750 mg, 1 vial + 1 diluent ampoule (6 mL)
Mustafa Nevzat Ilac Sanayii A.Ş. Prof. Dr. Bülent Tarcan Sok., Pak Iş Merkezi No: 5/1 34349 Gayrettepe/Istanbul.
Mustafa Nevzat Ilac Sanayii A.Ş. ÇobançeşmeMah.Sanayi Cad. No.13 Yenibosna-Istanbul.